Epizyme (EPZM) Tops Q2 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
Go back to Epizyme (EPZM) Tops Q2 EPS by 10c
August 14, 2014 2:00 PM EDT
Epizyme, Inc. (NASDAQ: EPZM) is surging higher today on strong volume. Shares are up 17% at last check.
Yesterday, the company posted Q2 results that beat expectations and provided a corporate update. On Monday, the company reported pre-clinical data and early clinical observations... More
August 12, 2014 5:01 PM EDT
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, reported pre-clinical data and early clinical observations from an ongoing Phase 1 trial, being conducted in collaboration with Eisai, the Institut Gustave Roussy, and the Institut Bergonie, of EZH2 inhibitor EPZ-6438 (E7438) in patients with advanced solid tumors and B-cell lymphomas. These data were presented today by Robert Copeland, Ph.D., Chief Scientific Officer, Epizyme, during an oral session on novel therapeutics in lymphoma at the American Society of Hematology (ASH) meeting on Lymphoma Biology, held... More
